Arteaga-Henríquez, Gara http://orcid.org/0000-0002-1251-8988
Rosales-Ortiz, Silvia Karina
Arias-Vásquez, Alejandro
Bitter, Istvan
Ginsberg, Ylva
Ibañez-Jimenez, Pol
Kilencz, Tünde
Lavebratt, Catharina
Matura, Silke
Reif, Andreas
Rethelyi, Janos
Richarte, Vanesa
Rommelse, Nanda
Siegl, Anne
Ramos-Quiroga, J. Antoni
Funding for this research was provided by:
Horizon 2020 (Nº728018)
Article History
Received: 13 May 2019
Accepted: 30 December 2019
First Online: 11 February 2020
Ethics approval and consent to participate
: Written consent will be obtained from every study participant. The Ethical Committee of the Department of Psychiatry, Psychosomatic Medicine and Psychotherapy at the University Hospital Frankfurt-Goethe University in Frankfurt, Germany, approved the study protocol on 14 November 2018 with protocol number 269/18. The ethical committee approval for the study protocol requested by Istvan Bitter, Department of Psychiatry and Psychotherapy, Semmelweis University, Budapest, Hungary, was issued by the Ministry of Human Capacities, dated 3 September 2019. The Ethical Committee of the University Hospital Vall d’Hebron in Barcelona, Spain, approved the study protocol on 11 January 2019 with protocol number 311/2018. An addendum was approved on 12 April 2019 with protocol number 311/2018.
: Not applicable.
: IB has served as an advisor/consultant in the last 5 years for Angelini, Eli Lilly, Gedeon Richter, and Pierre Fabre and has lectured for Eli Lilly, Janssen, Lundbeck, Gedeon Richter, and Servier. JARQ was on the speaker's bureau and/or acted as consultant for Eli Lilly, Janssen-Cilag, Novartis, Shire, Takeda, Bial, Shionogui, Lundbeck, Almirall, Braingaze, Sincrolab, Medice and Rubio in the last 5 years. He has also received travel awards (air-tickets + hotel accomodation) for taking part in psychiatric meetings organized by Janssen-Cilag, Rubio, Shire, Medice and Eli Lilly. The Department of Psychiatry, chaired by him, has received unrestricted educational and research support from Eli Lilly, Lundbeck, Janssen-Cilag, Actelion, Shire, Ferrer, Oryzon, Roche, Psious and Rubio in the last 5 years. YG has received speaker fees, has received reimbursement for travel costs, and/or has served as a consultat for Novartis, HB Pharma, Shire, Eli Lilly, Hogrefe, Broadman, Clarke Partners, Medscape, Medibas, and Natur & Kultur. All other authors declare that they have no competing interests.